NO20091664L - Farmaoytiske preparater av HDAC-inhibitorer og chelaterbare metallforbindelser samt metall-HDAC-inhibitor-chelatkomplekser - Google Patents

Farmaoytiske preparater av HDAC-inhibitorer og chelaterbare metallforbindelser samt metall-HDAC-inhibitor-chelatkomplekser

Info

Publication number
NO20091664L
NO20091664L NO20091664A NO20091664A NO20091664L NO 20091664 L NO20091664 L NO 20091664L NO 20091664 A NO20091664 A NO 20091664A NO 20091664 A NO20091664 A NO 20091664A NO 20091664 L NO20091664 L NO 20091664L
Authority
NO
Norway
Prior art keywords
metal
hdac inhibitor
chelate complexes
hdac
well
Prior art date
Application number
NO20091664A
Other languages
English (en)
Inventor
Arlene E Mckeown
Thomas A Miller
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20091664L publication Critical patent/NO20091664L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer farmasøytiske preparater av en HDAC-inhibitor og en chelaterbar metallforbindelse. I én utførelse tilveiebringer oppfinnelsen en fremgangsmåte for behandling av kreft og lindring av bivirkningene forbundet med HDAC-inhibitoren ved tilførsel av det farmasøytiske preparat. I en annen utførelse tilveiebringer foreliggende oppfinnelse også farmasøytiske preparater av metall-HDAC-inhibitorchelatkomplekser. I en tredje utførelse tilveiebringer oppfinnelsen fremgangsmåter for behandling av kreft ved tilførsel av de farmasøytiske preparatene. Oppfinnelsen tilveiebringer krystallinske preparater av metall-HDAC-inhibitor-chelatkomplekser og fremgangsmåter for fremstilling av disse
NO20091664A 2006-09-28 2009-04-27 Farmaoytiske preparater av HDAC-inhibitorer og chelaterbare metallforbindelser samt metall-HDAC-inhibitor-chelatkomplekser NO20091664L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84830006P 2006-09-28 2006-09-28
PCT/US2007/020609 WO2008039421A2 (en) 2006-09-28 2007-09-24 Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes

Publications (1)

Publication Number Publication Date
NO20091664L true NO20091664L (no) 2009-04-27

Family

ID=39230785

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091664A NO20091664L (no) 2006-09-28 2009-04-27 Farmaoytiske preparater av HDAC-inhibitorer og chelaterbare metallforbindelser samt metall-HDAC-inhibitor-chelatkomplekser

Country Status (14)

Country Link
US (2) US20090239946A1 (no)
EP (2) EP2079462A4 (no)
JP (1) JP2010504968A (no)
KR (1) KR20090064400A (no)
CN (1) CN101528212A (no)
AU (1) AU2007300532A1 (no)
BR (1) BRPI0717554A2 (no)
CA (1) CA2663569A1 (no)
CO (1) CO6190508A2 (no)
IL (1) IL197718A0 (no)
MX (1) MX2009003405A (no)
NO (1) NO20091664L (no)
RU (1) RU2009115860A (no)
WO (1) WO2008039421A2 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545968C (en) * 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
US20070249827A1 (en) * 2004-06-02 2007-10-25 Sandoz Ag Meropenem Intermediatein in Crystalling Form
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
EA018698B1 (ru) * 2005-09-21 2013-10-30 4Сц Аг Сульфонилпирролгидрохлориды как ингибиторы гистондезацетилазы
EP2404911A1 (en) * 2005-10-31 2012-01-11 Janssen Pharmaceutica NV Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
MX2008016008A (es) * 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
NZ576347A (en) * 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
WO2010043904A2 (en) 2008-10-15 2010-04-22 Generics [Uk] Limited Improved process
WO2010062333A1 (en) * 2008-10-27 2010-06-03 Plus Chemicals Sa Polymorphs of vorinostat and vorinostat potassium salt and process for preparation thereof
WO2010061219A2 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Polymorphs
NZ601967A (en) 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
KR20130101524A (ko) * 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
TWI483721B (zh) 2013-09-05 2015-05-11 Profeat Biotechnology Co Ltd The use of a composition containing a ferrous amino acid chelate for the manufacture of anti-cancer medicaments
CA2898771C (en) * 2013-09-05 2017-01-03 Profeat Biotechnology Co., Ltd. Use of composition containing ferrous amino acid chelate in preparation of anti-cancer medicament
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
KR20170012555A (ko) * 2014-06-12 2017-02-02 더 유니버시티 오브 노트르 담 듀락 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법
CA2980801A1 (en) 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
IL326637A (en) * 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP2022552642A (ja) * 2019-10-07 2022-12-19 ヴィラクタ サブシディアリー，インク． 副作用が軽減されたｈｄａｃ治療の調剤
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1574822A (en) * 1976-03-23 1980-09-10 Lafon Labor Acetohydroxamic acid derivatives and pharmaceutical compositions thereof
US4315942A (en) * 1979-05-21 1982-02-16 New England Medical Center, Inc. Intravenously administrable iron supplement
US4335116A (en) * 1980-10-07 1982-06-15 University Patents, Inc. Mineral-containing therapeutic compositions
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4613616A (en) * 1984-07-20 1986-09-23 Research Corporation Polymeric iron chelators
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
EP0855024A4 (en) 1995-09-20 2001-08-22 Merck & Co Inc HISTONE DEACETYLASE AS THE ATTACK POINT FOR ANTIPROTOZOIC ACTIVE SUBSTANCES
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AUPP505798A0 (en) 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
BR0014254A (pt) 1999-09-08 2002-08-27 Sloan Kettering Inst Cancer Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
ATE361316T1 (de) * 1999-09-08 2007-05-15 Sloan Kettering Inst Cancer Kristallstruktur einer deacetylase und deren inhibitoren
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
WO2005110399A2 (en) * 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
AU2005280211A1 (en) * 2004-08-25 2006-03-09 Merck Sharp & Dohme Corp. Histone deacetylase inhibitors
US7799937B2 (en) * 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions

Also Published As

Publication number Publication date
CN101528212A (zh) 2009-09-09
RU2009115860A (ru) 2010-11-20
JP2010504968A (ja) 2010-02-18
US20090239946A1 (en) 2009-09-24
CO6190508A2 (es) 2010-08-19
EP2436382A1 (en) 2012-04-04
EP2079462A2 (en) 2009-07-22
CA2663569A1 (en) 2008-04-03
MX2009003405A (es) 2009-04-09
AU2007300532A1 (en) 2008-04-03
WO2008039421A3 (en) 2008-07-24
EP2079462A4 (en) 2009-12-02
KR20090064400A (ko) 2009-06-18
IL197718A0 (en) 2009-12-24
WO2008039421A2 (en) 2008-04-03
US20120142770A1 (en) 2012-06-07
BRPI0717554A2 (pt) 2013-10-29

Similar Documents

Publication Publication Date Title
WO2008039421A3 (en) Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
IL198116A0 (en) Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
UA109417C2 (uk) ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
EP4285906A3 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
MX2009004984A (es) Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.
MX2009004077A (es) Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
UA94129C2 (ru) Соединения для ингибирования митоза
UA96126C2 (ru) Соединение для ингибирования активности rho киназы, фармацевтическая композиция, которая содержит такое соединение, и способ ингибирования активности rho киназы
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
MY148634A (en) Pyridazinone derivatives
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
EA200970680A1 (ru) N-замещенные производные глицина: ингибиторы гидроксилаз
JO2998B1 (ar) مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX2009013625A (es) Compuestos de di (arilamino) arilo.
JO2962B1 (en) Aminopronic derivatives substituted as niprilicin inhibitors
EA200700601A1 (ru) Производные фениламинопиримидина как ингибиторы bcr-abl
WO2010065512A3 (en) Compounds for treating proliferative disorders
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
NO20085317L (no) Imidazoazepinonforbindelser
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
WO2009015368A3 (en) Multikinase inhibitors for use in the treatment of cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application